The 43rd National Pharmaceutical Industry Information Annual Conference and the 2026 Beijing · Changping Life Science Forum opened at Beijing
The 43rd National Pharmaceutical Industry Information Annual Conference and the 2026 Beijing · Changping Life Science Forum opened at Beijing Changping Future Science City on July 12.
More than 800 participants, including academicians and experts, along with relevant leaders from national ministries, Beijing Municipality, and Changping District, as well as representatives from research institutes, industry associations, pharmaceutical companies, and investment institutions, attended the opening ceremony and the main forum.
At the opening ceremony, a series of major releases and launching ceremonies were held, systematically reviewing industrial development achievements, consolidating global cooperation consensus, and reinforcing the industrial ecosystem. The event premiered the “Top 10 Innovative Breakthroughs in the Pharmaceutical Industry during the 14th Five‑Year Plan,” systematically summarizing landmark achievements: record‑high approvals of innovative drugs; accelerated translation and application of frontier biotechnologies; coordinated domestic and international market efforts for innovative drugs; notable progress in preserving and innovating traditional Chinese medicine; intensive emergence of innovative achievements in high‑end medical devices; accelerated growth of a number of innovative enterprises; advancement of the pharmaceutical industry’s internationalization toward higher‑end segments; continued improvement in collaborative development along the pharmaceutical industrial chain; in‑depth promotion of digital‑intelligent transformation and AI‑empowered full‑scenario applications; and systematic upgrading of the green pharmaceutical manufacturing system. These comprehensively demonstrate the milestone achievements of China’s pharmaceutical industry during this phase.
The event simultaneously released the 2026 key actions of the “Global Cooperation and Development Initiative for the Pharmaceutical Industry,” systematically laying out six major directions: innovation synergy, digital‑intelligent integration, industrial chain linkage, joint standard‑setting, green and low‑carbon development, and accessibility for people’s livelihoods. The initiative aims to deepen pragmatic global pharmaceutical collaboration and enhance the global supply security of medical and health products. Eleven representatives from research institutes, leading enterprises, and industry organizations, including Rao Zihe, Cao Xuetao, Dong Jiahong, and Wang Cunyu, jointly took the stage to launch the initiative, clarifying development paths and consolidating the foundation for high‑quality, sustainable, and international development of China’s pharmaceutical industry during the “15th Five‑Year Plan” period.
Three major platforms were simultaneously launched and established in Changping: the Beijing Future Science City Synthetic Biology Manufacturing Pilot Platform, the Changping Branch Center of the Beijing Intellectual Property Protection Center, and the Life Science Park Branch Center of the Zhongguancun Intellectual Property Protection Center.
Jiang Jiandong, Academician of the Chinese Academy of Engineering and President of the Institute of Materia Medica, Chinese Academy of Medical Sciences, innovatively proposed a “molecular group” theory for new drug R&D focusing on China’s original drugs. Yang Ting, Director of the Department of Drug Registration at the NMPA, attended and spoke. Xu Na, Deputy Director of the Department of Medical Services Management at the National Healthcare Security Administration, presented the achievements and future plans for supporting innovative drug development through medical insurance. Alessio Mora, a technical officer from the World Health Organization, called on all countries to jointly improve the full‑chain support system for chronic disease prevention and treatment. Ma Zheng, Member of the Party Leadership Group and Deputy Director of the Beijing Municipal Healthcare Security Administration, introduced the “Several Measures of Beijing Municipality to Support High‑Quality Development of Innovative Pharmaceuticals (2026).”
In the enterprise sharing session, Lyu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., shared the internationalization practices of a local pharmaceutical company. Naresh Narasimhan, a senior executive from Danaher Corporation, shared the “two‑way empowerment” cooperation layout of multinational enterprises.
The conference also announced the “2025 Top 100 Chinese Pharmaceutical Industrial Enterprises by Main Business Revenue.” Guo Wen, Director of the China Pharmaceutical Industry Information Center, provided an interpretation of the annual performance of these top 100 enterprises.
The roundtable dialogue entitled “Full‑Chain Support for Innovative Drugs – Engine and Track for Pharmaceutical Innovation during the 15th Five‑Year Plan” was moderated by Zhang Wei, President of the China Society for Drug Regulation. Wang Cunyu, Foreign Academician of the Chinese Academy of Engineering and Member of the U.S. National Academy of Medicine and President of the Peking University Advanced Institute of Clinical Medicine; Yang Qing, President of the China Maternal and Child Health Association; Zhao Yong, Vice President of Shanghai Pharmaceuticals Holding Co., Ltd.; Zhu Yi, Chairman of Baili Tianheng; Zhu Hailuan, Vice President of Greater China at Sanofi (China) Investment Co., Ltd.; and Gan Quan, Managing Director of SDIC Merchants Investment, held in‑depth discussions on topics such as the engines for innovative drug development during the “15th Five‑Year Plan” period and the implementation of full‑chain support policies.
The roundtable dialogue on “AI and Pharmaceutical Innovation – New Paradigms at the Technological Frontier and New Industrial Ecosystems” was moderated by Wu Haidong, Vice President of the China Pharmaceutical Enterprise Association. Xiu Yuan, President of Xiuzheng Pharmaceutical Group Co., Ltd.; Zhao Chao, President of Shandong Buchang Pharmaceutical Co., Ltd.; Zhang Guimin, Chairman of Lunan Pharmaceutical Group Co., Ltd.; Su Xuejun, Chairman of Shijiazhuang No.4 Pharmaceutical Co., Ltd.; Sun Yuhang, President of Beijing Tide Pharmaceutical Co., Ltd.; An Meng, Chairman of the Board and President of Konsen Pharmaceutical Group Co., Ltd.; and Wang Feng, Party Secretary and Senior Vice President of Simcere Pharmaceutical Group, engaged in lively discussions on cutting‑edge topics including AI‑empowered drug R&D, intelligent manufacturing, clinical trials, and industrial ecosystem restructuring.
This forum runs for two days (July 11–12) under the theme “Explore Life, Create the Future,” adopting a “1+9+N+AI” model. In addition to the opening ceremony and main forum, it features 9 high‑quality thematic sub‑forums and N special branded events, with AI elements deeply empowering the entire chain. In‑depth discussions are held on subsectors including AI empowerment, financial investment, synthetic biology, cell and gene therapy, high‑end medical devices, and international industrial cooperation.
Media Contact
Company Name: China National Pharmaceutical Industry Information Center
Contact Person: Pan Shan
Email: Send Email
City: Beijing
State: Beijing
Country: China
Website: https://www.cphiic.com/pageIndex
